2024

1. Janus kinase inhibitors and tumour necrosis factor inhibitors show a favourable safety profile and similar persistence in rheumatoid arthritis, psoriatic arthritis and spondyloarthritis: real-world data from the BIOBADASER registry

   Annals of the Rheumatic Diseases, Vol. 83, Núm. 9, pp. 1189-1199